Last €1.42 EUR
Change Today +0.133 / 10.33%
Volume 0.0
DYBN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:16 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DYBN) Snapshot

Open
€1.37
Previous Close
€1.29
Day High
€1.42
Day Low
€1.37
52 Week High
10/4/13 - €2.41
52 Week Low
05/10/13 - €1.10
Market Cap
120.3M
Average Volume 10 Days
258.3
EPS TTM
€-0.67
Shares Outstanding
84.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DISCOVERY LABORATORIES INC (DYBN)

Related News

No related news articles were found.

discovery laboratories inc (DYBN) Related Businessweek News

No Related Businessweek News Found

discovery laboratories inc (DYBN) Details

Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing life-saving products for critical-care patients with respiratory disease and care in pulmonary medicine. Its drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant), as well as in liquid, lyophilized, and aerosolized dosage forms; and develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company’s product includes SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants. It is also developing AEROSURF, a drug-device combination product that is in Phase IIa clinical trials for the treatment of RDS in premature infants; and AFECTAIR devices, which are novel disposable aerosol-conducting airway connectors for infants. The company has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

126 Employees
Last Reported Date: 03/17/14
Founded in 1992

discovery laboratories inc (DYBN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $461.7K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $406.7K
Compensation as of Fiscal Year 2012.

discovery laboratories inc (DYBN) Key Developments

Discovery Laboratories Inc. Announces Management Appointments

Discovery Laboratories Inc. announced new appointments to the company's management team. William C. Roberts has joined the company as Vice President, Investor Relations and Corporate Communications. In addition, John A. Tattory has been appointed Senior Vice President and Chief Financial Officer. Both Mr. Roberts and Mr. Tattory will report to John G. Cooper, President and Chief Executive Officer. Prior to joining the company, Mr. Roberts spent ten years with ViroPharma Incorporated (recently acquired by Shire), most recently serving as Vice President, Corporate Communications, with responsibility for investor and media relations, patient and physician advocacy, disease awareness, and commercial support. Previously, Mr. Roberts spent 12 years with MedImmune Inc. in various scientific and investor relations roles of increasing responsibility. Mr. Tattory joined Discovery Labs in 2008 and has served since then as Vice President, Finance. Mr. Tattory is a Certified Public Accountant with more than 20 years of finance and accounting experience, including eight years with Ernst & Young LLP and eight years with Bristol-Myers Squibb (BMS).

Discovery Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Operating Cash Outflows Guidance for the First Quarter of 2014

Discovery Laboratories Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter ended December 31, 2013, the company reported grant revenue of $74,000 against $195,000 for the same period a year ago. Operating loss was $10,265,000 against $12,425,000 for the same period a year ago. Net loss was $11,729,000 or $0.16 loss per common share against $6,815,000 or $0.16 loss per common share for the same period a year ago. For the full year, the company reported grant revenue of $388,000 against $195,000 for the same period a year ago. Operating loss was $44,508,000 against $37,819,000 for the same period a year ago. Net loss was $45,215,000 or $0.82 loss per common share against $37,315,000 or $0.95 loss per common share for the same period a year ago. For the first quarter of 2014, the company anticipates operating cash outflows before financing activities of approximately $11 million.

Discovery Laboratories Inc., Q4 2013 Earnings Call, Mar 13, 2014

Discovery Laboratories Inc., Q4 2013 Earnings Call, Mar 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYBN:GR €1.42 EUR +0.133

DYBN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $37.97 USD +0.23
View Industry Companies
 

Industry Analysis

DYBN

Industry Average

Valuation DYBN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 378.8x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 168.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit www.discoverylabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.